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Abstract
Alzheimer’s disease (AD) is the most common form of dementia,
and neuroinflammation is an important hallmark of the pathogen-
esis. Tumor necrosis factor (TNF) might be detrimental in AD,
though the results coming from clinical trials on anti-TNF inhibi-
tors are inconclusive. TNFR1, one of the TNF signaling receptors,
contributes to the pathogenesis of AD by mediating neuronal cell
death. The blood–cerebrospinal fluid (CSF) barrier consists of a
monolayer of choroid plexus epithelial (CPE) cells, and AD is associ-
ated with changes in CPE cell morphology. Here, we report that
TNF is the main inflammatory upstream mediator in choroid
plexus tissue in AD patients. This was confirmed in two murine AD
models: transgenic APP/PS1 mice and intracerebroventricular (icv)
AbO injection. TNFR1 contributes to the morphological damage of
CPE cells in AD, and TNFR1 abrogation reduces brain inflammation
and prevents blood–CSF barrier impairment. In APP/PS1 transgenic
mice, TNFR1 deficiency ameliorated amyloidosis. Ultimately,
genetic and pharmacological blockage of TNFR1 rescued from the
induced cognitive impairments. Our data indicate that TNFR1 is a
promising therapeutic target for AD treatment.
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Introduction
Alzheimer’s disease (AD) is the leading cause of dementia, with a
prevalence of about 10% after the age of 65 (Hebert et al, 2013;
Prince et al, 2015). AD is a chronic and progressive neurodegenera-
tive disease characterized by brain atrophy and accumulation of
amyloid b (Ab) plaques in the brain parenchyma and neurofibrillary
tangles in the neurons (Querfurth & Laferla, 2010). The importance
of soluble Ab oligomers (AbO)—the intermediate form between
monomeric Ab and Ab fibrils—has gained increasing attention as the
major toxic species driving the neuroinflammation associated with
Alzheimer’s disease rather than the Ab plaques themselves (Nitta
et al, 1997; Brkic et al, 2015b; Ferreira et al, 2015; Viola & Klein,
2015). Neuroinflammation is an important hallmark of brain pathol-
ogy (Akiyama et al, 2000), and both acute and chronic inflammation
are associated with cognitive decline (Holmes et al, 2009).
Tumor necrosis factor (TNF) is a pleiotropic pro-inflammatory
cytokine and a key mediator in many inflammatory disorders, such
as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA),
as well as neurodegenerative diseases such as Parkinson’s disease
and AD (Probert, 2015). Besides its inflammatory role, TNF func-
tions in the brain as a gliotransmitter secreted by neurons and glial
cells. It regulates synaptic communication between neurons and
thereby regulates brain function in health and in disease (Stellwagen
& Malenka, 2006; McCoy & Tansey, 2008). It has been proposed that
the effects of TNF on synapses are associated with the synaptic
dysfunction that plays a central role in AD, and particularly in
cognitive decline (Tobinick, 2009). Clinical evidence for the involve-
ment of TNF in AD comes from the co-localization of TNF with Ab
plaques and the elevated TNF levels in the plasma and cere-
brospinal fluid (CSF) of AD patients, both of which have been asso-
ciated with clinical deterioration (Fillit et al, 1991; Dickson, 1997;
Paganelli et al, 2002; Tarkowski et al, 2003a,b; Yasutake et al,
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2006; Swardfager et al, 2010). In addition, it has been speculated
that TNF contributes to amyloidogenesis in AD (Blasko et al, 1999)
and that chronic neuronal TNF overexpression promotes brain
inflammation, which is detrimental to neuronal viability (Janelsins
et al, 2008). Epidemiological studies indicate that AD is less preva-
lent in patients on anti-TNF blockers for rheumatoid arthritis (Chou
et al, 2016), but clinical trials using anti-TNF blockers in AD
patients have been inconclusive (Tobinick et al, 2006; Tobinick &
Gross, 2008). Furthermore, studies in mice raise questions about the
use of pan-TNF inhibitors in AD (Montgomery et al, 2011). TNF can
signal through two distinct receptors: TNF receptor 1 (TNFR1) and
TNFR2. Activation of TNFR1 leads to pro-inflammatory and neuro-
toxic activities, whereas triggering TNFR2 leads to immunomodula-
tion and has neuroprotective roles. It has been shown that TNFR1
protein levels and binding affinity in AD brains are increased, while
TNFR2 levels and binding affinity are decreased compared to non-
demented patients (Zhao et al, 2003; Cheng et al, 2010). Addition-
ally, Li et al (2004) reported that in the AD brain, TNFR1 mediates
Ab-induced neuronal cell death. Moreover, it is believed that TNFR1
plays a role in amyloidogenesis by regulating b-secretase (BACE1),
one of the enzymes important for processing amyloid precursor
protein (APP). In contrast, inhibition of TNFR2 increased Ab toxicity
in vitro (Shen et al, 1997), showing the importance of preserving
TNFR2 so that it can perform its functions in the neuroprotective
pathways. Moreover, when transgenic APP23 mice (a model of AD)
were backcrossed in a TNFR2-deficient background, they displayed
exacerbated AD pathology compared to APP23 mice with a func-
tional TNFR2 gene (Jiang et al, 2014). Also, selective inhibition of
neuronal TNFR2 enhanced the Ab- and Tau-related pathologic
features of AD and diminished the activation of microglia, which is
needed for clearance of Ab (Montgomery et al, 2013). These obser-
vations indicate that while TNFR1 plays detrimental roles in AD,
TNFR2 needs to be preserved in order to counteract the Ab-
mediated pathology. This requires selective targeting of the TNF
pathway.
Numerous studies indicate that neurovascular dysfunction and
perturbation of the central nervous system (CNS) barriers contribute
to the onset and progression of AD (Zenaro et al, 2017). The CNS is
strictly protected against external toxic insults by two important
barriers: the blood–brain barrier (BBB) and the blood–CSF barrier.
The choroid plexus is a highly vascularized specialized structure in
the ventricles of the brain consisting of a monolayer of cuboidal
choroid plexus epithelial (CPE) cells. These cells produce CSF and
form the blood–CSF barrier. The apical side of CPE cells faces the
CSF and contains numerous microvilli. In contrast to the BBB,
which is formed by tightly connected endothelial cells, the capillar-
ies of the choroid plexus are highly fenestrated, whereas the CPE
cells are firmly interconnected, separating blood from CSF (Balusu
et al, 2016a; Gorle et al, 2016; Vandenbroucke, 2016). Conse-
quently, the basal side of the choroid plexus is in contact with mole-
cules in the blood, but the blood–CSF barrier prevents their passage
to the brain parenchyma. Only active transport of specific molecules
across the barrier is allowed. Accordingly, the choroid plexus
system is actively involved in physiological processes and is essen-
tial for maintaining brain homeostasis (Vandenbroucke, 2016). The
choroid plexus is also an important sensor of inflammatory stimuli
in the blood (Vandenbroucke et al, 2012; Balusu et al, 2016a,b),
and it may act as a selective gateway to the brain for the trafficking
of immune cells (Demeestere et al, 2015). However, in AD this gate-
way system is altered, resulting in suboptimal recruitment of
inflammation-resolving immune cells to the brain (Baruch et al,
2015). In addition, numerous changes in choroid plexus morphol-
ogy and function in AD have been described (Serot et al, 2000,
2003, 2012; Brkic et al, 2015b). Additionally, there is a clear
inflammatory signature in the choroid plexus of transgenic AD mice
but not in age-matched WT littermates (Mesquita et al, 2015).
We recently found that intracerebroventricular (icv) injection of
Ab1–42 oligomers (AbO) induces choroid plexus inflammation and
loss of the blood–CSF barrier integrity, which was linked to
increased activity of matrix metalloproteinases (MMPs) (Brkic et al,
2015b). In our present study, we show that TNF/TNFR1 signaling is
the main axis contributing to CNS neuroinflammation in transgenic
AD mice and upon AbO injection in WT mice. We demonstrate that
TNFR1 deficiency protects against structural and functional impair-
ment of the choroid plexus and eventually rescues cognitive decline.
Furthermore, we provide proof of concept that pharmacological
inhibition of TNFR1 can prevent the AbO-associated cognitive
decline.
Results
TNF is the top upstream regulatory cytokine in the choroid
plexus of late-stage AD patients
Numerous papers have highlighted the importance of the choroid
plexus in AD (Serot et al, 2000, 2003, 2012; Brkic et al, 2015b). In
the current study, we performed a microarray analysis to identify
genes that are differentially expressed in human choroid plexus
tissue obtained post-mortem from late-stage AD patients and from
healthy controls. The ages of these subjects were 79  2.9 and
58  5.6 years, respectively, and thus were slightly different. Before
analysis, the quality of the microarray data was stringently checked.
Samples that did not pass hybrid quality control were excluded from
analysis.
We analyzed differentially expressed genes in the choroid plexus
of AD patients by using ingenuity pathway analysis (IPA; Fig 1).
IPA recognizes the cascade of upstream transcriptional regulators
that explains the differential expression and thereby identifies
changes in biological activities. The z-score was determined for
several upstream transcriptional regulators, with focus on upstream
cytokines. A z-score > 0 indicates that the upstream transcriptional
regulator has significantly more “activated” than “inhibited” predic-
tions, and vice versa for a z-score < 0. As shown in Fig 1A,
“upstream regulator analysis” in IPA revealed that TNF and IL1b
were the most prevalent activated upstream transcriptional regula-
tors of cytokines (z-score of 6.98 and 6.53, respectively). Other pro-
inflammatory genes (such as IL6 and IFNG) were also found
upstream of the differentially expressed genes (z-score 5.38 and
4.92, respectively). Strikingly, TNF itself was not differentially
expressed in the choroid plexus of late-stage AD patients (data not
shown). Therefore, we looked for genes downstream of TNF that
are differentially expressed in the choroid plexus. Figure 1B shows
that the expression of 157 TNF-dependent genes was altered in the
choroid plexus of late-stage AD patients, and most of them were
upregulated (indicated in red). Therefore, TNF also directly induces
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pro-inflammatory cytokines such as IL6 and members of the IL1-
signaling pathway such as IL1 receptor 1 (IL1R1). Further, analysis
of the overlap between the top 20 upregulated genes in the dataset
and the differentially expressed genes downstream of TNF (Fig 1C)
revealed that the TNF-dependent changes in gene expression were
very pronounced.
A
B
C
D
Figure 1. Ingenuity pathway analysis analysis of microarray results of human choroid plexus of late-stage AD patients.
Ingenuity pathway analysis (IPA) was used to identify the pathways of differentially expressed genes in the choroid plexus of patients with late-stage Alzheimer’s disease
(AD) compared to age-matched healthy controls.
A Identification of upstream cytokine mediators in the choroid plexus of AD patients. The upstream mediators are ranked according to their z-score (left axis) and
P-value (right axis).
B Network of differentially expressed genes downstream of TNF in the choroid plexus of late-stage AD patients compared to age-matched healthy controls
(red = upregulated, green = downregulated).
C Venn diagram of the top 20 differentially expressed genes and the differentially expressed genes downstream TNF.
D Overlay of the dataset on the canonical pathway of the TNF/TNFR1 [red = upregulated (with log ratio), green = downregulated (with log ratio)].
ª 2018 The Authors EMBO Molecular Medicine e8300 | 2018 3 of 22
Sophie Steeland et al TNFR1 as target in Alzheimer’s disease EMBO Molecular Medicine
Published online: February 22, 2018 
The pro-inflammatory signaling pathway of TNF is mediated by
signaling through TNFR1 and generally leads to the induction of
globally activated transcription factors such as NF-jB (Wajant &
Scheurich, 2011; Sedger & McDermott, 2014). This is also clear in
our dataset (red in Fig 1D). Though TNFRSF1a was not upregulated
in the choroid plexus of late-stage AD patients, NF-jB activity was
clearly upregulated.
NF-jB-dependent genes are upregulated in transgenic AD mice
and upon AbO injection in wild-type mice
Next, we studied the expression of several NF-jB-induced genes in a
transgenic mouse model for amyloidogenesis (APP/PS1 mice)
(Radde et al, 2006). We first determined the induction of several
NF-jB-dependent genes in the choroid plexus and hippocampus,
which is the key brain region involved in the formation of new
memory and the first region that exhibits neurodegeneration in AD
(Hollands et al, 2016). Figure 2A and B compares APP/PS1tg/wt
mice with age-matched non-transgenic littermates (APP/PS1wt/wt).
Analysis of the choroid plexus (Fig 2A) and hippocampus
(Fig 2B) of late-stage APP/PS1tg/wt mice showed that several pro-
inflammatory genes were significantly induced. The most
pronounced upregulated genes in the choroid plexus of transgenic
mice were of Il6, Nos2, Lcn2, Mmp8, and Mmp13. Interestingly, in
agreement with the data obtained from human AD patients, Tnf and
Tnfrsf1a were not differentially expressed in the choroid plexus of
APP/PS1tg/wt mice. However, in the hippocampus, Tnf and Tnfrs-
f1a, as well as Cxcl9 and Lcn2, were significantly induced.
The APP/PS1 transgenic mouse model mimics important hall-
marks of human AD pathology. To study the direct effects of Ab, we
A B
C D
Figure 2. Analysis of NF-jB-dependent genes in APP/PS1 mice and in Ab1–42 oligomer (AbO)-injected wild-type (WT) mice.
A–D Fold change in mRNA gene expression in the choroid plexus and hippocampus determined by qPCR of late-stage APP/PS1tg/wt mice compared with age-matched
control mice (A, B) (n = 3–4/group) and of C57BL6/J WT mice 6 h after intracerebroventricular (icv) injection with AbO (1 lg/ml) compared to icv injection with
scrambled peptide (C, D) (n = 5–7/group).
Data information: Bars represent mean  SEM. qPCR was normalized to stable housekeeping genes, determined by GeNorm. Statistics between control mice and AD
mice were done with an unpaired t-test, *0.01 ≤ P < 0.05; **0.001 ≤ P < 0.01; ***0.001 ≤ P < 0.0001, ****P < 0.0001.
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injected 5 ll of 1 lg/ml oligomerized Ab1–42 (AbO) in the cerebral
ventricles (icv) of wild-type (WT) mice as described (Brkic et al,
2015b). It has been shown that Ab and its deposits cause chronic
inflammation in AD, so this simple but reliable model is used to
investigate how AbO interferes with neuronal processes and to test
the efficacy of new therapeutic approaches (Akiyama et al, 2000;
Balducci & Forloni, 2014). Six hours after icv injection of AbO,
inflammation was evident in the choroid plexus as well as in the
hippocampus. In both brain regions, multiple inflammatory and NF-
jB-dependent genes were significantly upregulated. These include
Il6, Il1b, Nos2, Cxcl9, and several MMPs, as well as Nf-jb itself
(Fig 2C and D). Strikingly, the fold induction of the inflammatory
genes in choroid plexus and hippocampus was hundred to thousand
times higher in this model of AbO-induced toxicity than in the
respective brain structures of APP/PS1tg/wt mice. Moreover, in
contrast to the absence of Tnf expression in chronic AD pathology
in choroid plexus of mouse and human, Tnf was significantly
induced in the two brain structures in the acute AbO toxicity model.
Also, the expression of Tnfrsf1a and Tnfrsf1b in the choroid plexus
was also significantly higher.
TNFR1 deficiency reduces the inflammatory signature in the
choroid plexus and hippocampus in transgenic AD mice and upon
AbO injection
Our observations in late-stage AD patients and in the two AD mouse
models show that TNF and NF-jB signaling are important in AD
pathology. As TNF signaling via TNFR1 is an important activator of
NF-jB, we studied the effect of abrogating TNFR1 in the choroid
plexus and hippocampus of AD mice. First, we crossed APP/PS1tg/wt
mice with TNFR1-deficient mice and determined inflammatory gene
expression in the choroid plexus and the hippocampus at late-stage
AD mice and compared the results with age-matched control mice.
We focused on NF-jB-dependent genes that were upregulated in
one or both mouse models. Interestingly, though TNFR1 deficiency
did not prevent the induction of all determined genes in the two
brain regions of APP/PS1tg/wt mice, it did affect the expression of
several potent inflammatory mediators. In the choroid plexus,
expression of Il6 and Cxcl9 was significantly decreased, but Nos2
expression was unaltered (Fig 3A–C). In agreement with the data in
Fig 2A, Nos2 and Il1b expression was not increased in the
hippocampus of APP/PS1tg/wt mice, so it was also not affected by
TNFR1 deficiency (Fig 3E and F). However, expression levels of
Cxcl9 and Tnf were significantly lower in APP/PS1tg/wt mice in the
TNFR1/ background compared to the WT background (Fig 3G
and H). Interestingly, Lcn2 expression was significantly induced in
the choroid plexus and hippocampus of APP/PS1tg/wt mice (Fig 2A).
In the choroid plexus, the induction was significantly weaker in the
TNFR1/ background (Fig 3D).
To investigate the effects of TNFR1 deficiency on the direct
response to AbO, TNFR1/ mice were injected icv with AbO or
with scrambled peptide (control), and expression of inflammatory
genes was studied in the choroid plexus and hippocampus 6 h later.
Although AbO did significantly induce the expression of pro-inflam-
matory genes Il6, Nos2, and Cxcl9 in the choroid plexus of TNFR1/
mice compared to control mice, this induction was significantly
reduced in the absence of TNFR1 compared to WT mice (Fig 3I and
K). Also, the expression of Il1b and Tnf was significantly reduced in
this setting (data not shown). Strikingly, expression of Il1b, Nos2,
Cxcl9, and Tnf in the hippocampus was completely abrogated in
AbO-injected TNFR1/ mice with similar levels as in scrambled
injected controls (Fig 3M–P). In agreement with the results obtained
in APP/PS1tg/wtTNFR1/ mice, also in the choroid plexus of AbO-
injected TNFR1/ mice Lcn2 expression was reduced compared to
WT mice (Fig 3L), but in the hippocampus there was no change
(data not shown). In summary, our studies in both AD mouse
models confirmed the importance of TNF/TNFR1 signaling in the
inflammation associated with AD pathology.
TNFR1 deficiency protects the choroid plexus against
morphological changes induced by AbO and in APP/PS1 mice
The choroid plexus is morphologically altered in AD patients (Mar-
ques et al, 2013). We previously showed the direct detrimental
effects of AbO on the morphology of CPE cells due to inflammation
and impairment of the blood–CSF barrier (Brkic et al, 2015b). To
examine the effect of TNFR1 deficiency on the morphology of the
CPE cells, we injected WT and TNFR1/ mice icv with either AbO
or scrambled control and studied the structural alterations in CPE
cells 6 h later by transmission electron microscopy (TEM) and
volume scanning electron microscopy (SEM). Figure 4A and B
shows that CPE cells of WT and TNFR1/ mice injected with
scrambled peptide appear morphologically normal. In contrast, CPE
cells of AbO-injected WT mice lost their cuboidal structure and the
microvilli on the apical side are fewer, shorter, and disorganized
(Fig 4C). Conversely, the morphology of CPE cells of AbO-injected
TNFR1/ mice is preserved (Fig 4D): The cells are cuboidal and
the microvilli appear normal. To better comprehend the overall dif-
ferences in shape and ultrastructure of CPE cells between AbO-
injected WT and TNFR1/ mice, we made use of volume SEM
(Brkic et al, 2015b). Serial block-face SEM (SBF-SEM) is an applica-
tion used to generate electron microscopy image stacks that are
reconstructed to generate 3D images (Denk & Horstmann, 2004).
We performed SBF-SEM on en bloc-stained CP samples and the
generated datasets were used for manual segmentation of the CPE,
allowing the 3D visualization of the cell shape at nanometer resolu-
tion. As shown in Fig 5D, mainly the microvilli of the choroid
plexus of AbO-injected TNFR1/ mice were preserved compared to
the choroid plexus of AbO-injected TNFR1+/+ mice, whereas the
typical cuboidal shape of the choroid plexus of TNFR1/ also
shows some alterations upon AbO injection (Fig 5A–D; Movies
EV1–EV4).
To confirm these results in a transgenic model of AD, we
dissected the choroid plexus from 18-week-old APP/PS1tg/wt mice in
a WT and TNFR1/ background and from age-matched non-trans-
genic counterparts. We investigated the structural alterations of the
CPE cells with TEM (Fig EV1) and SEM (Fig EV2 and Movies EV5–
EV8) and found that 18-week-old non-transgenic littermates, that is,
APP/PS1wt/wt mice both in WT and TNFR1/ background, exhib-
ited almost no morphological changes (Fig EV1A and B). Some of
the CPE cells show a limited alteration in their cuboidal cell struc-
ture as they are more point-shaped; however, this can be considered
as a normal process in the choroid plexus (Gorle et al, 2016). The
cytoplasm and mitochondria are nicely preserved in mice of that
age. Contrastingly, TEM images of the CPE cells of age-matched
APP/PS1tg/wt mice in a WT background displayed a profound
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transformation into cells with a more degenerative state (Fig EV1C).
Indeed, the cytoplasm of these cells is translucent, indicative for
cellular degradation and the nuclei have irregular shapes (Fig EV1C,
zoom). It is also clear that the capillaries of the choroid plexus are
swollen and dilated, and filled with a lot of red blood cells. TNFR1
deficiency in APP/PS1tg/wt mice clearly protects the morphology of
the CPE cells at several levels. There are less signs of cellular degra-
dation, the CPE cells are still cuboidal as observed in non-transgenic
littermates, and the mitochondria and nuclear shape are preserved
(Fig EV1D and zoom). Also the capillaries are less swollen and less
red blood cells are observed. In contrast to what we observed in
AbO-injected mice, the transgenic APP/PS1tg/wt mice showed no
severe loss of microvilli alignment (Figs 4C and D, and EV1C and
D). Next, SEM analysis of the CPE cells of APP/PS1 mice confirmed
our observations made by the TEM: CPE cells of APP/PS1wt/wt mice
show some signs of aging-related damage which is much more
pronounced in a APP/PS1tg/wt mice and this is prevented in
TNFR1/ background (Fig EV2A–D, Movies EV5–EV8).
TNFR1 deficiency protects against blood–CSF barrier impairment
by reduced MMP expression and maintenance
To investigate the mechanisms at the molecular level behind the
protection in TNFR1/ mice, we examined blood–CSF barrier
permeability by measuring leakage of 4 kDa FITC-dextran into the
CSF 6 h after icv injection of AbO. We previously reported that icv
A B C D
E F G H
I J K L
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Figure 3. TNFR1 deficiency abrogates inflammation in choroid plexus and hippocampus.
A–H Relative mRNA gene expression of Il6, Nos2, Cxcl9, and Lcn2 in the choroid plexus (A–D) and of Il1b, Nos2, Cxcl9, and Tnf in the hippocampus (E–H) of late-stage AD
APP/PS1tg/wt mice in a TNFR1+/+ and TNFR1/ background compared to age-matched APP/PS1wt/wt mice (n = 2–4/group).
I–P Relative mRNA gene expression of Il6, Nos2, Cxcl9, and Lcn2 in the choroid plexus (I–L) and of Il1b, Nos2, Cxcl9, and Tnf in the hippocampus (M–P) of C57BL/6J
TNFR1+/+ and TNFR1/ mice 6 h after intracerebroventricular (icv) injection with scrambled peptide or with AbO (1 lg/ml) (n = 4–5/group).
Data information: Bars represent mean  SEM. qPCR was normalized to stable housekeeping genes, determined by GeNorm. Statistics were performed with an unpaired
t-test, *0.01 ≤ P < 0.05; **0.001 ≤ P < 0.01; ***0.001 ≤ P < 0.0001, ****P < 0.0001.
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injection of AbO affects blood–CSF barrier integrity and disturbs
barrier function (Brkic et al, 2015b). Here, AbO significantly
increased blood–CSF permeability in WT mice compared to control
mice injected with scrambled peptide (Fig 6A). In contrast, icv AbO
injection did not induce blood–CSF barrier leakage in TNFR1/
mice. Given that disruption of the blood–CSF barrier has been linked
to increased activity of matrix metalloproteinases (MMPs) in the
choroid plexus (Brkic et al, 2015b), we investigated their expression
6 h after icv injection of AbO. Expression of bothMmp3 andMmp8 in
the choroid plexus was significantly increased after icv AbO injection
to what we reported previously (Brkic et al, 2015b), but this increase
was significantly less in TNFR1-deficient mice (Fig 6B and C).
As the integrity of the blood–CSF barrier is maintained by junc-
tional proteins between the CPE cells, and MMPs are known to
disrupt tight junctions (TJs) (Vandenbroucke et al, 2012; Brkic et al,
2015b), we used qPCR and immunohistochemistry to determine
whether TJs in the choroid plexus of TNFR1/ mice were
preserved after AbO injection. In line with previous observations in
mouse models and human AD patients (Bergen et al, 2015; Brkic
et al, 2015b), 6 h after AbO injection claudin-5 (Cldn5) expression
was significantly downregulated in WT mice but not in TNFR1/
mice (Fig 6D). The expression of occludin (Ocln) after AbO injection
was also significantly weaker in WT mice but not in TNFR1/ mice
(Fig 6E). Claudin-1 (Cldn1) mRNA levels were unaltered upon AbO
injection in both genotypes (data not shown), but the subcellular
localization of CLDN1 does show alterations (Fig 6F). Six hours
after AbO injection, CLDN1 remained at the apical side of the CPE
cells of injected TNFR1/ mice (Fig 6F, arrows), whereas in WT
mice it became more diffuse, its expression weakened, and is less
obviously prominent in the apical region (Fig 6F, arrowheads).
TNFR1 deficiency reduces Ab levels and plaque disposition in
APP/PS1 mice
We further assessed the pathological consequences of TNF/TNFR1
signaling in the transgenic AD mice by characterizing different
A
B
C
D
Figure 4. TNFR1 deficiency protects against AbO-induced morphological alterations of the choroid plexus determined by TEM.
A–D Representative conventional transmission electron microscopy (TEM) images of the choroid plexus 6 h after intracerebroventricular (icv) injection of scrambled
peptide (control) (A, B) or Ab1–42 oligomers (AbO, 1 lg/ml) (C, D) in C57BL/6J TNFR1
+/+ (A, C) and TNFR1/ (B, D) mice (n = 2/group). In scrambled-injected control
mice (A, B), the cuboidal structure of the choroid plexus epithelial (CPE) cells is preserved and the microvilli are aligned and structured (insert). The cuboidal
structure of the CPE cells in AbO-injected WT mice (C) is altered, and the microvilli are shortened (insert). In contrast (D), CPE cells of TNFR1/ mice icv injected
with AbO have a normal morphology and the microvilli are organized (insert). The TEM images were taken at a magnification of 1,000×, and scale bar represents
10 lm; inserts were taken at a magnification of 3,000×, and scale bar represents 2 lm.
ª 2018 The Authors EMBO Molecular Medicine e8300 | 2018 7 of 22
Sophie Steeland et al TNFR1 as target in Alzheimer’s disease EMBO Molecular Medicine
Published online: February 22, 2018 
hallmarks of AD. APP/PS1 mice aged 4–12 months display an
increase in plaque burden (Radde et al, 2006). To determine
whether genetic inactivation of TNFR1 influences Ab plaque forma-
tion in APP/PS1tg/wt mice, we visualized the Ab plaques with Thio-
flavin-S in brain sections of APP/PS1tg/wt mice in a WT and a
TNFR1/ background. Thioflavin-S stains mature Ab plaques in
the b-sheet conformation and the signal increases with increased Ab
oligomerization. In contrast to age-matched control mice (not
shown), APP/PS1tg/wt mice showed plaque formation (Fig 7A, C,
and D), and the brains of TNFR1-deficient APP/PS1tg/wt mice had
significantly less Thioflavin-S+ areas. This indicates that b-sheet
formation and thus probably Ab oligomerization are reduced in the
absence of TNFR1, although this reduction is fairly modest. As the
size of the plaques is indicative of the severity of the Ab pathology
(Zhou et al, 2005), we performed a morphometric analysis on the
brain sections stained with Thioflavin-S (Fig 7B). This analysis
demonstrates that there are significantly fewer of the smaller
plaques (< 10 lm2) in APP/PS1tg/wt mice deficient in TNFR1 and
that there is a tendency for medium-sized Ab plaques (10–20 lm2)
to also be fewer. However, no reduction in number was observed in
larger Ab plaques (> 20 lm²).
Since the genetic deletion of TNFR1 reduces Ab burden in trans-
genic AD mice, we questioned whether TNFR1 deficiency in APP/
PS1tg/wt mice can affect total Ab levels. There is strong evidence that
mainly soluble Ab drives disease progression in AD rather than the
amyloid deposits themselves, and Ab42 is considered the most neuro-
toxic form (Chen & Glabe, 2006). Therefore, we used ELISA to
measure the levels of both soluble and insoluble Ab40 (S-Ab40 and IS-
Ab40) and Ab42 (S-Ab42 and IS-Ab42) in the cortex of APP/PS1
tg/wt
mice, because the amyloid plaque deposition starts at the age of
A
B
C
D
Figure 5. TNFR1 deficiency protects against AbO-induced morphological alterations in the choroid plexus determined by SBF-SEM.
A–D Representative serial block-face scanning electron microscopy (SBF-SEM) images of the choroid plexus 6 h after intracerebroventricular (icv) injection of scrambled
peptide (control) (A, B) or Ab1–42 oligomers (AbO, 1 lg/ml) (C, D) in C57BL/6J TNFR1
+/+ (A, C) and TNFR1/ mice (B, D) (n = 2/group), derived from Movies EV1–EV4.
CSF: cerebrospinal fluid; Mv, microvilli; Nu, nucleus. Scale bar, 5 lm.
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about 6 weeks in this region (Maia et al, 2013). As shown in Fig 7E–
H, the levels of all Ab peptides were significantly higher in the corti-
cal brain fraction of APP/PS1tg/wt mice than in non-transgenic litter-
mates of the same age. In APP/PS1tg/wt TNFR1/ mice, S-Ab42
levels were significantly lower (Fig 7F). Moreover, in line with the
Ab plaque deposition, the cortical levels of IS-Ab42 were also
decreased, although not significantly, compared to WT APP/PS1tg/wt
mice (Fig 7H). Conversely, the levels of S-Ab40 and IS-Ab40 were not
significantly changed in the absence of TNFR1 (Fig 7E and G).
Previous studies reported that TNFR1 signaling affects the produc-
tion of Ab by inducing the transcription of beta-secretase 1 (BACE1)
(He et al, 2007; Yamamoto et al, 2007). As we could show that dele-
tion of TNFR1 in APP/PS1tg/wt mice results in a reduced Ab
pathology, we determined the gene expression levels of Bace1 in the
hippocampus of APP/PS1tg/wt in a WT and TNFR1/ background
and compared it with age-matched non-transgenic littermates. As
expected, Bace1 expression was significantly increased in APP/PS1tg/
wt mice, but importantly, this induction was completely prevented
when the TNF/TNFR1 signaling pathway is deleted (Fig 7I).
TNFR1 deficiency prevents microglia activation in APP/PS1 mice
and upon icv injection of AbO
Microglia activation is a prominent hallmark of AD pathology, and it
is well documented that both AbO and Ab fibrils activate microglia
(Sondag et al, 2009). Activated microglia propagate brain
A B
D
F
E
C
Figure 6. TNFR1 deficiency protects the blood–cerebrospinal fluid (CSF) barrier by preventing MMP increase and preserving tight junctions.
A Blood–CSF barrier permeability was determined by measuring leakage of FITC-labeled dextran in the CSF of C57BL/6J TNFR1+/+ and TNFR1/ mice 6 h after
intracerebroventricular (icv) injection of either scrambled peptide or Ab1–42 oligomer (AbO 1 lg/ml) (n = 11–14/group).
B–E Relative mRNA gene expression of Mmp8, Mmp3, Cldn5, and Ocln in choroid plexus of TNFR1+/+ and TNFR1/ mice 6 h after icv injection of 1 lg/ml AbO
(n = 5–6/group).
F Representative images of CLDN1 staining in choroid plexus of the fourth ventricle of TNFR1+/+ (left and middle image) and TNFR1/ mice (right image) 6 h after
icv injection with either 1 lg/ml AbO (middle and right image) or scrambled peptide (left image). Arrows indicate preserved CLDN1 tight junctions, and arrowheads
indicate affected CLDN1 tight junctions (n = 3/group). Scale bar represents 15 lm.
Data information: Bars represent mean  SEM. qPCR was normalized to stable housekeeping genes determined by GeNorm. The experiments are done in duplicates,
and pooled results are shown in (A) and representative results in (B–E). Statistics were performed with a one-way ANOVA for the permeability data (A) and an unpaired
t-test for the qPCRs (B–E), *0.01 ≤ P < 0.05; **0.001 ≤ P < 0.01; ***0.001 ≤ P < 0.0001, ****P < 0.0001.
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inflammation further and induce neuronal cell loss by releasing
neurotoxic mediators in the brain (Parajuli et al, 2013). As this
process plays a pivotal role in the progression of AD, we assessed
microglial activation in the two different AD models by examining
brain sections stained for IBA1, which is a microglia-specific marker.
Given the inflammatory signature in choroid plexus and hippocam-
pus of APP/PS1tg/wt and AbO-injected WT mice, and the reduction
in TNFR1/ mice, we quantified the microglia on whole-brain
sections. Counting IBA1-positive microglia showed an increase in
brains of late-stage APP/PS1tg/wt mice (Fig 8A and B) and in brains
of WT mice 6 h after icv injection of AbO (Fig 8C and D), compared
to their respective controls. In both AD models, this was significantly
reduced in TNFR1-deficient background (Fig 8A–D).
TNFR1 deficiency protects against memory decline in APP/PS1tg/wt
mice and induced by icv injection of AbO
Cognitive impairment is one of the most important hallmarks of AD
(Ledo et al, 2013; Ferreira et al, 2015; Jongbloed et al, 2015).
Cognitive decline (spatial learning, measured by the radial four-arm
maze assay) has been reported in APP/PS1 mice (Radde et al,
2006). Microglia activation precedes cognitive decline in several AD
mouse models (Parajuli et al, 2013), and soluble AbO is involved in
the induction of cognitive impairment (Ferreira et al, 2015).
In our study, we evaluated cognitive behavior using the novel
object recognition test (NOR), which assesses working memory
based on the differences in exploration time of novel and familiar
objects (Antunes & Biala, 2012). We found that both short-term
memory (STM) and long-term memory (LTM) in APP/PS1tg/wt
mice were indeed diminished compared to age-matched control
mice: Their NOR performance was significantly lower: 65% vs.
49%, P < 0.001 for STM, and 64% vs. 51%, P = 0.02 for LTM.
Though for STM the novel object preference of TNFR1-deficient
APP/PS1tg/wt mice was not significantly better (57%) than that of
APP/PS1tg/wt mice with functional TNFR1 (49%) (Fig 9A), for
LTM their novel object preference was significantly better (67%
vs. 51%, P = 0.01) (Fig 9B). Moreover, LTM assessment revealed
that the preference of APP/PS1tg/wt TNFR1/ mice for novel
A B C D
E
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F G H
Figure 7. TNFR1 deficiency reduces Ab pathology in APP/PS1 mice.
A–D Brain sections of late-stage C57BL/6J APP/PS1tg/wt and APP/PS1tg/wtTNFR1/ mice were stained with Thioflavin-S to detect Ab disposition in the whole brain. The
amount of plaques was quantified (A), and a morphometric analysis was performed (B) (n = 5 and 6 mice/group, respectively). Representative images (C, D) of
Thioflavin-S (ThioS) staining of the brain containing the hippocampus of late-stage APP/PS1tg/wt and age-matched APP/PS1tg/wtTNFR1/ mice (scale bar represents
200 lm).
E–H ELISA analysis of soluble and insoluble Ab1–40 and Ab1–42 in the cortex of late-stage APP/PS1
tg/wt in a TNFR1+/+ and TNFR1/ background compared to age-
matched controls (n = 8, 9, and 3 mice, respectively).
I Relative mRNA expression of Bace1 in the hippocampus of late-stage APP/PS1tg/wt mice in a TNFR1+/+ and TNFR1/ background compared to age-matched
APP/PS1wt/wt mice (n = 5/group).
Data information: Bars represent mean  SEM. qPCR was normalized to stable housekeeping genes determined by GeNorm. Statistics were performed with an unpaired
t-test (A), a two-way ANOVA assay (B) or a one-way ANOVA (E–I), *0.01 ≤ P < 0.05; ***0.001 ≤ P < 0.0001; ****P < 0.0001.
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objects was as good as that of the non-transgenic WT mice of the
same age (64% vs. 67%).
Next, we assessed STM and LTM with the NOR test in WT mice
upon icv injection of AbO and compared this with WT mice injected
with scrambled peptide and TNFR1/ mice injected with AbO. As
expected, WT mice injected with scrambled peptide had a novel
object preference of about 67%, indicating a functional STM. In
contrast, WT mice injected with AbO showed a reduced novel object
preference (53%), indicative for AbO-induced memory decline
(P = 0.003). However, in TNFR1/ mice, icv injection of AbO did
not lead to STM decline, and their novel object preference (63%)
was significantly higher than in AbO-injected WT mice (P = 0.046;
Fig 9C). The same pattern was observed for LTM (Fig 9D). AbO
injection in TNFR1/ mice resulted in LTM performance resem-
bling that of mice injected with scrambled peptide (60% vs. 62%,
respectively) and was significantly better than AbO-injected WT
mice (53%, P = 0.04). Collectively, these results demonstrate that
TNFR1 deficiency interferes with the AbO-induced brain inflamma-
tion and ameliorates the subsequent memory impairment. This
finding indicates that TNFR1 has an important role in AD pathogen-
esis and its associated cognitive decline.
Treatment with an anti-TNFR1 biologic recapitulates the effects
of TNFR1 deficiency
Our results show that TNF/TNFR1 signaling is involved in the
pathology of AD, which makes it a potential therapeutic target. We
wanted to provide full proof of concept for therapeutic TNFR1-
targeting by assessing both STM and LTM. For this experiment, we
used an in-house generated trivalent anti-TNFR1 Nanobody called
TROS (Steeland et al, 2015). Nanobodies have many advantages
compared to antibodies when they are intended for chronic therapy
or brain delivery (Steeland et al, 2016). Since TROS inhibits human
TNFR1 (hTNFR1) but shows no cross-reactivity with mouse TNFR1,
therapeutic studies with TROS have to be performed in transgenic
mice that express hTNFR1 in a mouse TNFR1/ background
(hTNFR1 Tg) (Steeland et al, 2017). First, to exclude any TROS or
Nanobody-related effect on inflammation upon icv injection, we
administered TROS together with AbO via icv injection in WT mice
which lack the therapeutic target of TROS, followed by choroid
plexus isolation and qPCR analysis. We determined the expression
of several inflammatory genes, for example, Il6, Il1b, Tnf, Mmp3,
and Tnfrsf1a in the choroid plexus upon AbO injection together with
PBS and compared it with AbO/TROS co-injection. These results
show that TROS neither induces nor blocks AbO-induced inflamma-
tion in the absence of its target (Fig EV3). Next, we assessed the
effect of TROS on the memory performance in AbO-injected hTNFR1
Tg mice, which are mice that express the target of TROS. The prefer-
ence for novel objects of hTNFR1 Tg mice injected with scrambled
peptide resembles that of normal WT mice (65%), indicating that
their STM is sustained at normal levels. When these mice were icv
injected with AbO, the preference for novel objects declined due to
STM impairment (53%, P = 0.03). Co-injection of TROS (1.55 lg/
ll) with AbO (1 lg/ml) significantly prevented STM decline: Prefer-
ence for novel objects was the same as in hTNFR1 Tg mice injected
with scrambled peptide (68%, P = 0.007; Fig 9E). Similar results
were obtained for LTM: Preference for novel objects of mice co-
injected with TROS was not significantly worse than the scrambled
peptide mouse group (65% vs. 79%, P = 0.052) but not significantly
better than in mice co-injected with vehicle (56%, P = 0.2; Fig 9F).
In conclusion, our data demonstrate that TNFR1 is a valuable new
drug target to treat AbO-induced cognitive decline.
Discussion
Alzheimer’s disease (AD) is a chronic, progressive, neurodegenera-
tive disease with a totally unmet need for drugs that prevent the
continuing and long-term cognitive decline, as no FDA-approved
drug meets this criterion (Citron, 2010). Neuroinflammation, a
prominent hallmark of AD, occurs very early during disease progres-
sion and is mediated by the production of pro-inflammatory media-
tors and activated glial cells that affect different brain regions
(Akiyama et al, 2000). Epidemiological studies linked the use of
anti-inflammatory medication to a lower incidence of AD, but strate-
gies to target the relevant pathways in patients with established AD
have not been successful (Miguel-Alvarez et al, 2015). TNF is a very
potent pleiotropic pro-inflammatory cytokine, and there is a vast
body of data showing its involvement in the pathology of AD. In the
brain, TNF is expressed by microglia, astrocytes, and neurons, and
genetic polymorphisms associated with TNF upregulation have been
linked to AD susceptibility (Ramos et al, 2006). TNF signals via
TNFR1 and TNFR2. In agreement with the harmful role of TNFR1 in
other neurodegenerative diseases (Probert, 2015), several studies in
mice have shown that this signaling pathway is detrimental in AD
(Li et al, 2004; He et al, 2007). The role of TNFR1 contrasts sharply
with that of TNFR2, to which multiple beneficial functions in the
CNS have been attributed, such as its prominent role in protection
of neurons against Ab toxicity (Shen et al, 1997; Jiang et al, 2014;
Probert, 2015).
In our study, we demonstrated that in late-stage AD patients,
TNF as well as IL1B and IL6 are the main upstream regulatory
cytokines in the choroid plexus resulting in TNFR1-dependent acti-
vation of NF-jB. This potent transcription factor, which is activated
▸Figure 8. TNFR1 deficiency prevents microglia activation in APP/PS1 mice and upon icv AbO injection.A, B IBA1 staining for microglia on whole-brain sections of late-stage C57BL/6J APP/PS1tg/wt in a TNFR1+/+ and TNFR1/ background compared to age-matched
controls. (A) Representative images of a region around the fourth ventricle (microglia indicated with arrowheads) in age-matched controls (upper panel, n = 3),
APP/PS1tg/wtTNFR1+/+ (middle panel, n = 4), and APP/PS1tg/wtTNFR1/ (lower panel, n = 6) mice. (B) Quantification of IBA1+ cell count (determined by brown staining).
C, D IBA1 staining for microglia on whole-brain sections of C57BL/6J TNFR1+/+ mice 6 h after intracerebroventricular (icv) injection with either scrambled peptide or
Ab1–42 oligomer (AbO, 1 lg/ml) or TNFR1
/ mice icv injected with AbO. (C) Representative images of a region around the fourth ventricle (microglia indicated with
arrowheads) in scrambled-injected mice (upper panel, n = 2) and in AbO-injected TNFR1+/+ (middle panel, n = 3) and TNFR1/ mice (lower panel, n = 3). (D)
Quantification of IBA1+ cell count (determined by brown staining).
Data information: Scale bars represent 100 lm and insert 20 lm. Bars represent mean  SEM. Statistics were performed with a one-way ANOVA assay,
*0.01 ≤ P < 0.05; **0.001 ≤ P < 0.01.
◀
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Figure 9. Genetic or therapeutic blockage of TNFR1 prevents cognitive decline in APP/PS1tg/wt mice and upon icv AbO injection.
Analysis of short-term memory (STM) and long-term memory (LTM) evaluated by the novel object recognition (NOR) test.
A, B STM (A) and LTM (B) assessed in C57BL/6J APP/PS1wt/wtTNFR1+/+ mice (n = 19) and APP/PS1tg/wt mice in a TNFR1+/+ (n = 10) and TNFR1/ background (n = 11)
aged 30–34 weeks.
C, D STM (C) and LTM (D) assessed 24 h after intracerebroventricular (icv) injection of either scrambled peptide or Ab1–42 oligomer (AbO, 1 lg/ml) in C57BL/6J TNFR1
+/+
or TNFR1/ mice (n = 6–11/group).
E, F STM (E) and LTM (F) assessed in human TNFR1 transgenic (hTNFR1 Tg) mice 24 h after icv injection of scrambled peptide, AbO alone (1 lg/ml), or AbO combined
with a trivalent anti-TNFR1 Nanobody (TROS, 1.55 lg/ll) (n = 6–8/group).
Data information: Min-to-max box plots represent median with the 25 and 75% percentiles, and whiskers are the min and max values  SEM. The mean values are
indicated above the graphs. All experiments were done in duplicates, and pooled results are shown. Statistics were performed with a one-way ANOVA assay,
*0.01 ≤ P < 0.05; **0.001 ≤ P < 0.01; ****P < 0.0001.
ª 2018 The Authors EMBO Molecular Medicine e8300 | 2018 13 of 22
Sophie Steeland et al TNFR1 as target in Alzheimer’s disease EMBO Molecular Medicine
Published online: February 22, 2018 
by TNF/TNFR1 interaction, elevates the expression of several
inflammatory genes and amplifies neuroinflammation (Yang et al,
2002a; Wajant & Scheurich, 2011). The expression of TNF itself is
not increased in late-stage AD patients, indicating that TNF is an
early inflammatory inducer in the AD pathology that initiates the
inflammatory cascade in the choroid plexus. A limitation of our
study is the small age difference between the healthy subjects and
AD patients. Consequently, some of the changes might be caused by
aging, rather than Alzheimer’s disease. Therefore, we also studied
the involvement of NF-jB in two different mouse models of AD. As
a first model of amyloidosis, we used transgenic mice expressing
human amyloid precursor protein (APP) and presenilin 1 (PS1).
This transgenic AD model displays several cellular and behavioral
characteristics of AD, including development of cerebral Ab plaques
and cognitive impairment (Radde et al, 2006). For the second
model, we injected oligomerized Ab1–42 (AbO) into the brain ventri-
cles to study the direct toxic effects of AbO species. Also this model
mimics key pathological characteristics of AD, such as tau hyper-
phosphorylation, neuronal cell loss, and impairment of hippocam-
pus-dependent memory, making this a relevant model to study the
amyloid-driven component of AD pathogenesis (Nitta et al, 1997;
Brouillette et al, 2012; Cetin et al, 2013; Balducci & Forloni, 2014).
In both models, we confirmed NF-jB-induced inflammation in the
choroid plexus and hippocampus. Similar to the choroid plexus
expression in late-stage AD patients, the expression of Tnf was not
elevated in the choroid plexus of late-stage APP/PS1 mice. Conver-
sely, Tnf is highly expressed in both choroid plexus and hippocampus
of wild-type (WT) mice icv injected with AbO. Also the expression of
other inflammatory genes was 100–1,000 times higher after AbO injec-
tion in WT mice compared to the respective expression in APP/PS1
mice. This might be partially explained by the fact that the injected
AbO is fourfold higher than the levels measured in APP/PS1 mice
(Maia et al, 2013). Moreover, chronic exposure to an inflammatory
trigger such as Ab might exhaust and/or desensitize inflammation-
responsive cells. As APP/PS1 mice are continuously exposed to toxic
Ab species throughout their life, this might explain the lower induc-
tion of inflammatory genes in these mice. Interestingly, also the
expression of lipocalin 2 (Lcn2), which is known to silence TNFR2-
mediated neuroprotective signaling cascades, is elevated in the
choroid plexus of mice in both models (Naude et al, 2012).
One report showed that Ab1–40 physically interacts with TNFR1,
thereby contributing to neuronal death (Li et al, 2004), and here we
demonstrate that TNFR1 deficiency prevents AbO-induced
inflammation in the choroid plexus and hippocampus. Based on
these findings, we suggest that not only TNF but also AbO, poten-
tially via direct TNFR1 binding, is responsible for the inflammation
in these two brain regions.
The choroid plexus is an often neglected brain structure that
contains one of the CNS barriers, called the blood–cerebrospinal fluid
(CSF) barrier. Several studies have shown structural alterations in the
morphology and functionality of the choroid plexus in AD patients,
including epithelial atrophy, irregular basement thickening of CPE
cells, and decreased CSF secretion (Serot et al, 2000, 2003, 2012;
Balusu et al, 2016a; Gorle et al, 2016). Moreover, Chalbot et al
(2011) pointed out that CPE damage may be one of the first signs of
AD. In agreement with these observations, we observed that Ab
oligomers alter the cuboidal shape of CPE cells. Also in the APP/PS1
model, we observed a high degree of morphological and cellular
damage in the choroid plexus. Notably, these pathological changes in
the choroid plexus were prevented by the absence of TNFR1 in both
models. We previously reported that icv injection of AbO increases
the leakiness of the blood–CSF barrier associated with decreased
expression of tight junction genes and proteins, and increased activity
of MMPs (Brkic et al, 2015b). Tight junctions are essential for main-
taining the integrity of several epithelial and endothelial barriers,
including the blood–CSF barrier. Their apical presence in CPE cells
restricts paracellular diffusion of molecules through this barrier
(Redzic, 2011; Zihni et al, 2016). MMPs, proteases that degrade
components of the extracellular matrix, are involved in several
neurodegenerative disorders (Brkic et al, 2015a). Additionally, we
and others have shown that MMPs can also disrupt structural
tight junction proteins of the BBB and blood–CSF barrier (Yang et al,
2007; Schubert-Unkmeir et al, 2010; Vandenbroucke et al, 2012).
Importantly, the choroid plexus is considered as a selective entry gate
for leukocytes into the CNS and essential for immunosurveillance of
the CNS. Consequently, changes in the choroid plexus anatomy and
integrity of the barrier might allow more leukocyte extravasation into
the brain parenchyma, which would exacerbate CNS inflammation
(Shrestha et al, 2014; Demeestere et al, 2015).
In our previous study, we speculated that these detrimental events
in the choroid plexus are caused by a cascade of upstream pro-inflam-
matory mediators (Brkic et al, 2015b). Here, we confirmed this
hypothesis by showing that TNFR1 signaling is the main pathway
involved in these detrimental events in the choroid plexus. Indeed,
we confirmed that TNFR1 deficiency prevents the increase in blood–
CSF barrier permeability because MMP expression in the choroid
plexus is not increased and the choroid plexus tight junctions are
preserved. Bergen et al (2015) pointed out that Cldn5 is the main
gatekeeper for paracellular transport across the blood–CSF barrier
and that its down-regulation is responsible for the blood–CSF barrier
leakage. As TNFR1 deficiency preserves Cldn5 expression in the
choroid plexus after AbO triggering, this might be an important reason
why the blood–CSF barrier is preserved in TNFR1-deficient mice.
MMP3 is designated as the most important MMP responsible for
barrier leakage in AbO-induced toxicity (Brkic et al, 2015b), and its
expression as well as that of Mmp8 is reduced in TNFR1 null mice.
This might have a substantial effect because MMP8 is known to
impair the blood–CSF barrier in inflammatory conditions (Vanden-
broucke et al, 2012). Here, we identified TNF signaling via TNFR1
as the main regulator of AbO-induced damage to the choroid plexus
and the barrier. Whether or not TNFR1 abrogation also prevents
leukocyte recruitment to the CNS is not yet known and should be
addressed in future studies.
We also observed that TNFR1 deficiency might do more than
protect the CNS against inflammatory triggers from outside the CNS
by preserving the blood–CSF barrier; it might also impair the activa-
tion of resident microglia. Importantly, AbO induces the release of
TNF from microglia, which then stimulates it own release via
TNFR1 (Kuno et al, 2005). Thereby, a vicious feedback loop in the
activation of microglia is sustained, but this loop is broken by
TNFR1 deficiency.
A dual role for primed microglia has been described. In early
AD onset, microglia may contribute to clearance of Ab by phago-
cytosis, but later they initiate deleterious cascades by releasing
pro-inflammatory cytokines, which contribute to neuronal damage
(Agostinho et al, 2010; Yang et al, 2011; Wang et al, 2015).
14 of 22 EMBO Molecular Medicine e8300 | 2018 ª 2018 The Authors
EMBO Molecular Medicine TNFR1 as target in Alzheimer’s disease Sophie Steeland et al
Published online: February 22, 2018 
Interestingly, it has been shown that although peripheral human
TNF could modulate Ab pathology by increasing the phagocytic
activity of microglia, it contributes to neuronal damage and
synaptic loss as well (Paouri et al, 2017a). In contrast to these
results, it has also been shown that TNF inhibits phagocytosis of
Ab by microglia (Koenigsknecht & Landreth, 2004). As we observed
that TNFR1 ablation prevented the activation of microglia, this
might abrogate the sustained neuroinflammation and prevent
neuronal and synaptic loss. Because microglia are involved in Ab
clearance, the observed reduction in activated microglia might seem
to contradict our observations in APP/PS1tg/wtTNFR1/ mice,
which displayed a lower Ab burden and less plaque deposition.
However, it has been shown that in some conditions activated
microglia fail to clear Ab despite their abundance (Koenigsknecht &
Landreth, 2004). In our study, the reduced Ab burden could have
been a consequence of the down-regulation of the BACE1 promoter
activity rather than to increased clearance by microglia and this is
in agreement with the study of He et al (2007). Additionally, Paouri
et al recently found that TNF abrogation attenuates amyloid plaque
formation by restricting the activity of also PS1, one of the four core
proteins in the c-secretase complex responsible for APP processing,
in 5xFAD mice (Paouri et al, 2017b), but the involvement of TNFR1
in this process is not investigated.
Finally, the most promising finding of our study is that TNFR1
deficiency alleviated cognitive decline in both AD models. More-
over, TNFR1 inhibition by a Nanobody recapitulated these findings
Figure 10. Schematic hypothesis of the roles of TNFR1 in the pathology of Alzheimer’s disease.
Amyloid precursor protein (APP) is cleaved into pathogenic amyloid-beta 1–42 (Ab1–42) species by BACE1, the expression of which can be activated by TNFR1-induced NF-jB
in neurons of the hippocampus. Choroid plexus epithelial (CPE) cells are tightly connected with tight junctions. The presence of Ab oligomers (AbO) in the CSF leads, via
TNFR1, to induction of chemo- and cytokines (e.g., TNF) by CPE cells and other neuronal cells such as microglia and neurons. Upon AbO exposure, CPE cells also express
matrix metalloproteinases (MMPs), which disrupt tight junctions (right lower panel). Eventually, this results in leakage of the blood–CSF barrier. In the brain parenchyma,
TNF triggers TNFR1 molecules on the surface of microglia and consequently induces its own release. Additionally, TNF also promotes neuronal death via TNFR1. Ultimately,
all these events lead to further aggravation of neuroinflammation and to cognitive impairment.
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by protecting against AbO-induced memory impairment. Although
this could have been a consequence of the reduction in neuroin-
flammation and amyloid burden, it can also be a direct effect of
modulation of the synapses. Indeed, TNF has been shown to induce
the release of glutamate from microglia and astrocytes via TNFR1
signaling and might directly induce glutamate excitotoxicity via
TNFR1 through activation of AMPA receptors (Bezzi et al, 2001;
Kuno et al, 2005; Takeuchi et al, 2006). Conversely, TNFR2 activa-
tion protects against glutamate-induced excitotoxicity (Marchetti
et al, 2004; Olmos & Llado, 2014). Moreover, it has been shown
that selective inhibition of soluble TNF restores the synaptic
dysfunction and long-term potentiation impairment in 5XFAD mice
(MacPherson et al, 2017). Further research is needed to address
these possibilities in our established models.
In conclusion, we propose new mechanisms through which
TNFR1 might contribute to AD neuroinflammation and pathology, in
addition to its direct effect on neuronal cell death (Yang et al, 2002b;
Li et al, 2004; Fig 10). TNF/TNFR1 signaling leads to neuroin-
flammation in the choroid plexus and the hippocampus, contributing
to disruption of choroid plexus morphology and blood–CSF barrier
integrity. This may result in aggravation of CNS inflammation and
eventually to neuronal loss. Additionally, TNFR1 deficiency prevents
microglia activation, which results in reduced inflammation of the
brain parenchyma. We have also shown that impairment of TNF/
TNFR1 protects AD-susceptible mice against Ab-induced pathology.
Finally, both genetic and pharmacologic abrogation of TNFR1 signal-
ing rescued AD-associated cognitive impairment, which is the ulti-
mate consequence of all the destructive events in AD pathology.
Materials and Methods
Mice
For the experiments with intracerebroventricular (icv) injections of
oligomerized Ab1–42 (AbO), female C57BL/6J wild-type (WT) and
C57BL/6J TNFR1 knockout (KO) (TNFR1/) mice, aged 8–12 weeks,
were used and were housed in SPF conditions. B6-Tg(Thy1-APPswe;
Thy1-PS1 L166P) in a C57BL/6J background, further called
APP/PS1tg/wt, corresponding non-transgenic littermates (APP/PS1wt/wt)
and APP/PS1tg/wt mice in a TNFR1/ background were bred in a
conventional facility. TNFR1/ mice are described by Rothe et al
(1993), and the APP/PS1 mouse model is developed by Radde et al
The latter mice harbor the human APP transgene bearing Swedish
mutation (KM670/671NL) and PSEN1 L166P under control of Thy1
promoter (Radde et al, 2006). APP/PS1 mice were crossed into a
TNFR1 KO background. In all experiments, we used heterozygous
transgenic littermates that were age- and gender-matched. All mice
were housed with 14- to 10-h light and dark cycles and free access
to food and water. All experiments comply with the current laws of
Belgium and were approved by the animal ethics committee of
Ghent University.
Ingenuity pathway analysis
Human choroid plexus samples of AD patients and healthy controls
were obtained post-mortem at autopsy from patients with advanced
late-stage Alzheimer’s disease [Braak & Braak stage V–VI, mean age
79 years, 95% confidence interval (CI) (72.2–86.4)] and from healthy
controls [mean age 58 years, 95% CI (41.9–72.9)]. Samples were
immediately snap-frozen upon removal in liquid nitrogen. All
samples were obtained from 3.5 to 30 h post-mortem. All tissues
were stored at 80°C at the Brown University Brain Tissue for
Neurodegenerative Disorders Resource Center until processed. This
research application was reviewed and approved as meeting the stan-
dards for the protection of human subjects per 45CFR46/21CFR56 by
Rhode Island Hospital’s Committee on protection of human subjects.
The IRB for the Brain Bank falls under Project #0083-03. Since this is
a post-mortem de-identified study, the IRB decided that no formal
review was required (IRB Registration numbers: RIH IRB 1-0000396,
RIH IRB 2-00004624, TMH IRB-00000482). Gene expression was
analyzed by Ingenuity pathway analysis (IPA) (Ingenuity Systems,
www.ingenuity.com). A core analysis was performed, and networks,
canonical pathways, and functional enrichment in diseases and gene
function were determined. In our analysis, we mainly focused on
cytokines. Confirmed relationships (e.g., TarBase, IPA expert find-
ings) and relationships predicted (TargetScan) with at least moderate
confidence, as stated in IPA, were both accepted.
Preparation of Ab1–42 oligomers
Ab1–42 oligomers (AbO) were prepared as previously described
(Brkic et al, 2015b). Briefly, Ab1–42 (rPeptide; A-1163-1) or scram-
bled peptide (rPeptide; A-1004-1) was dissolved in hexafluoroiso-
propanol (HFIP; Sigma-Aldrich; 105228) at 1 mg/ml. Next, HFIP
was removed with a SpeedVac vacuum concentrator. The resulting
peptides were then dissolved in DMSO and purified using a 5 ml
HiTrap desalting column (GE Healthcare; 17-408-01). The mono-
meric Ab1–42 was eluted with Tris-EDTA buffer (50 mM Tris and
1 mM EDTA, pH 7.5). The eluted peptide concentration was
measured using Pierce Micro BCA Protein Assay (Thermo Scientific;
23225) according to the manufacturer’s guidelines. The peptides
were allowed to oligomerize at room temperature (RT) for 2 h,
followed by dilution to 1 lg/ml or 2 lg/ml in Tris-EDTA buffer. All
icv injections were performed within 2 h after oligomerization.
Intracerebroventricular (icv) injections
For the icv injections of scrambled peptide, AbO or AbO with
Armenian hamster anti-TNFR1 antibody (Ab) or TROS, mice were
anaesthetized with isoflurane and mounted on a stereotactic frame. A
constant body temperature was maintained using a heating pad. Injec-
tion coordinates were determined from the bregma (anteroposterior
0.07, mediolateral 0.1, dorsoventral 0.2) and were determined using
the Franklin and Paxinos mouse brain atlas. By using a Hamilton
needle, 5 ll of the either scrambled peptide or AbO (1 lg/ml) was
injected into the left lateral ventricle. For co-injections, 5 ll was
injected of a mixture of 2.5 ll AbO (2 lg/ml) and 2.5 ll of the triva-
lent anti-TNFR1 Nanobody TROS [1.55 mg/ml, (Steeland et al, 2015)].
Cerebrospinal fluid isolation
Cerebrospinal fluid (CSF) was harvested from the fourth ventricle
via the cisterna magna puncture method (Brkic et al, 2015b).
Briefly, borosilicate glass capillary tubes (Sutter Instruments; B100-
75-15) were used to make needles on the Sutter P-87 flaming
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micropipette puller (pressure 330 Pa, heat index 300). Mice were
anaesthetized, and the skin from the backside of the mice was
dissected and disinfected with 70% ethanol. The cisterna magna
membrane was exposed by separating the muscle tissue on the back
side of the scull, and the animal was mounted at an angle of 135°.
Subsequently, CSF was collected by puncturing the cisterna magna
membrane using the capillary needles.
Determination of blood–CSF barrier permeability leakage
One hour before CSF isolation, mice were intravenously (iv)
injected with 250 mg/kg FITC-labeled dextran (4 kDa, Sigma). A
CSF sample of 2 ll was diluted 50 times in PBS, and leakage from
the blood into the CSF was determined by measuring the fluores-
cence in the diluted CSF samples (kex/kem = 485/520 nm) using the
FLUOstar omega (Isogen LifeScience).
Tissue sample isolation
For RNA analysis, mice were transcardially perfused with a mixture
of 500 ml DPBS (Sigma), 1 ml heparin sodium (5,000 IU/ml, Wock-
hardt), and 0.5% bromophenol blue (Sigma) to remove all blood
and to label the choroid plexus for easy isolation. Choroid plexus
and hippocampus were isolated from brain tissue and snap-frozen
in liquid nitrogen for RNA analysis. For immunohistochemical anal-
ysis, mice were transcardially perfused with paraformaldehyde
(PFA) and brain samples were fixed in 4% PFA and processed for
paraffin-embedding.
Immunohistochemistry
For immunostaining on mouse brain sections, 5-lm sections were
prepared from paraffin-embedded samples. After dewaxing, samples
were treated with citrate buffer (Dako; S2031), followed by washing
in PBS. Endogenous peroxidase activity was blocked with 3% H2O2
in methanol for 10 min, and samples were blocked with 5% goat
serum in antibody diluent (Dako; S2022) for 30 min at RT, followed
by overnight incubation at 4°C with primary antibody against
claudin-1 (CLDN1, Invitrogen, 51-9000, 1:1,000) or IBA1 (Wako
Chemicals, 019-19741, 1:500). The next day, slides were washed
with PBS and incubated with secondary antibody coupled to HRP or
biotin, respectively (Dako; EK4003 and E0432). An amplification
step was performed using tyramide (TSA kit, Perkin Elmer) for
CLDN1-staining, and visualization was done using ABC (Vector)
and DAB. Slides were counterstained with hematoxylin, dehydrated,
and mounted with Entalan. Slides were scanned using a slide scan-
ner (ZEISS, Axio Scan) and analyzed with the Zen software (Carl
Zeiss Microscopy GmbH, 2012). Histological quantification of the
plaques in the whole brain was done with the Fiji software (Univer-
sity of Wisconsin-Madison) by color thresholding the brown color,
using the exact same parameters for all genotypes.
Transmission electron microscopy
The choroid plexus of the fourth ventricle was dissected from APP/
PS1 mice of 18-week-old in WT or TNFR1/ background, or from
WT or TNFR1/ mice 6 h after injection of AbO, and these were
fixed in 4% PFA and 2.5% glutaraldehyde in 0.1 M NaCacodylate
buffer, pH 7.2 for 4 h at RT followed by fixation O/N at 4°C. After
washing in buffer, they were post-fixed in 1% OsO4 with 1.5% K3Fe
(CN)6 in 0.1 M NaCacodylate buffer at RT for 1 h. After washing in
ddH2O, samples were subsequently dehydrated through a graded
ethanol series, including a bulk staining with 1% uranyl acetate at
the 50% ethanol step followed by embedding in Spurr’s resin.
Ultrathin sections of a gold interference color were cut using an
ultramicrotome (Leica EM UC6), followed by a post-staining in a
Leica EM AC20 for 40 min in uranyl acetate at 20°C and for
10 min in lead stain at 20°C. Sections were collected on formvar-
coated copper slot grids. Grids were viewed with a JEM 1400plus
transmission electron microscope (JEOL, Tokyo, Japan) operating
at 60 kV.
3D scanning electron microscopy
For 3D scanning electron microscopy (SEM), the choroid plexus of
the lateral ventricle was dissected from APP/PS1 mice of 18-week-
old in WT or TNFR1/ background, or from WT or TNFR1/ mice
6 h after injection of AbO and scrambled peptide, and was immedi-
ately transferred into fixation buffer (2% PFA, Sigma-Aldrich; 2.5%
glutaraldehyde, Electron Microscopy Sciences in 0.15 M Cacodylate
buffer, pH 7.4). After overnight fixation at 4°C, samples were
washed 3 × 5 min in Cacodylate buffer and subsequently osmicated
in 2% osmium (EMS), 1.5% ferrocyanide, and 2 mM CaCl2 in
Cacodylate buffer for 1 h on ice, and then extensively washed in
ultrapure water (UPW). This was followed by incubation in 1%
thiocarbohydrazide (20 min), washes in UPW, and a second osmi-
cation in 2% osmium in UPW (30 min). The samples were washed
5 × 3 min in UPW and placed in uranyl acetate replacement stain
(Electron Microscopy Sciences), 1:3 in water at 4°C overnight. The
following day, they were stained with Walton’s lead aspartate stain
for 30 min at 60°C. For this, a 30 mM L-aspartic acid solution was
used to freshly dissolve lead nitrate (20 mM, pH 5.5). The solution
was filtered after incubation for 30 min at 60°C. After the final
washes, the samples were dehydrated using a series of ice-cold solu-
tions of increasing EtOH concentration (30, 50, 70, 90, 2 × 100%),
followed by two dehydrations of 10 min in propylene oxide. Subse-
quent infiltration with resin (Spurr’s; EMS) was done by first incu-
bating the samples overnight in 50% resin in propylene oxide,
followed by at least two changes of fresh 100% resin. Next, samples
were embedded in fresh resin and cured in the oven at 65°C for
72 h.
For serial block-face imaging, the resin-embedded samples
were mounted on an aluminum specimen pin (Gatan) using
conductive epoxy (Circuit Works). The specimens were trimmed
in a pyramid shape using an ultramicrotome (Ultracut; Leica),
and the block surface was trimmed until smooth and at least a
small part of tissue was present at the block face. Next, samples
were coated with 5 nm Pt in a Quorum Q 150T ES sputter coater
(Quorum Technologies). The aluminum pins were placed in the
Gatan 3View2 in a Zeiss Merlin SEM for imaging at 1.6 kV with
a Gatan Digiscan II ESB detector. The Gatan 3View2 was set to
300 sections of 70 nm. IMOD (http://bio3d.colorado.edu/imod/)
and Fiji (Schindelin et al, 2012) were used for registration of the
3D image stack and conversion to TIFF file format. Representa-
tion of the cell in 3D movies and snapshots was done in Imaris
(BitPlane).
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Detection Ab plaques
Plaques of Ab in the brain were detected with a Thioflavin-S stain-
ing (binds b-rich structures). Thioflavin-S binds senile plaques—
extracellular Ab deposits—and neurofibrillary tangles, the two char-
acteristic lesions in AD patients. Ab is only present in senile
plaques, and thus, the antibody only detects the senile plaques. For
the Thioflavin-S staining (Sigma; T1892), PFA-fixed brain sections
of 8–10 lm were prepared from paraffin-embedded samples. After
dewaxing, sections were incubated with filtered 0.05% aqueous
Thioflavin-S (0.1 g Thioflavin-S in 200 ml 50% ethanol, Sigma;
T1892) for 5 min at RT. Next the sections were washed with 70 and
95% ethanol for 5 min, followed by three washing steps in PBS for
5 min. Next, the slides were incubated with DAPI (1:2,000) in PBS
for 30 min at RT. After washing with PBS and distilled H2O, the
slides were mounted with Mowiol-containing mounting medium.
Slides were scanned using a slide scanner (ZEISS, Axio Scan) and
analyzed with the Zen software (Carl Zeiss Microscopy GmbH,
2012). Histological quantification of the plaques in the whole brain
was done with the ImageJ software (https://imagej.net) by thresh-
olding the Thioflavin-S staining, using the exact same parameters
for all genotypes. Plaque burden was calculated as the area occu-
pied by the plaques, determined by the ImageJ particle counting
plug-in, divided by the total brain region area.
Ab extraction and ELISA
Both the soluble and insoluble Ab fractions—extracted from the
cortex—were determined with ELISA. For the extraction, tissue
was homogenized in Tissue Protein Extraction Buffer (10 ll per lg
cortex; Thermo Scientific) supplemented with protease inhibitor
(Thermo Scientific) and phosphatase inhibitor tablets (Sigma-
Aldrich) using a Precellys (Bertin Technologies). The beads in the
homogenized samples were spin down for 5 min at 5,000 g and
4°C. Supernatant was collected and centrifuged at 4°C for 1 h at
100,000 g (TLA 100 rotor). Supernatant containing the soluble Ab
fraction could directly be used for ELISA, while the pellet contain-
ing insoluble Ab is further processed. 2 ll GuHCl solution (6 M
GuHCl + 50 mM Tris–HCl) supplemented with protease inhibitor,
per lg cortex from which initially was started, was added to the
pellet containing the insoluble Ab fraction. The mixture was soni-
cated at following program 10 cycli 30 s on—30 s off, high ampli-
tude (BioruptorTM Sonication Device), and then, the mixture was
vortexed for 5 min and incubated for 60 min at 25°C. The mixture
was centrifuged at 4°C for 20 min at 70,000 g. The supernatant
was 12 times diluted with GuHCl diluent (0.26 g NaH2PO4.2H2O,
0.41 g Na2HPO4.2H2O, 16 ml 5 M NaCl, 0.8 ml 0.5 M EDTA, 1 ml
10% NaN3, 1.5 ml 10% CHAPS in 200 ml distilled H2O, pH 7,
supplemented with 10% BlockAce, 0.4 g BSA, and 1 protease inhi-
bitor tablet (Roche) prior to use) to prepare the samples for
ELISA.
To determine the Ab1–42 and Ab1–40 levels extracted out of the
cortex, 96-well immunoplates (Maxisorp Nunc; 430314) were
coated overnight (ON) at 4°C on a shaker with 50 ll per well anti-
Ab42 antibody (1.5 lg/ml; JRF/cAb42/26) or anti-Ab1–40 antibody
(1.5 lg/ml; JRF/cAb40/28) in coating buffer (10 mM Tris–HCl,
10 mM NaCl, 10 mM NaN3 in 500 ml distilled H2O, pH 8.5). Plates
were washed five times with PBST (PBS + 0.05% Tween-20), and
residual protein binding sites were blocked for 4 h at RT with
100 ll blocking buffer (0.1% casein buffer). 30 ll of either stan-
dard (Ab1–42; rPeptide or Ab1–40; rPeptide) or sample was mixed
with 30 ll detection antibody (JRF/ABN/25 coupled to HRPO
(Janssen Pharmaceutica), 1:2,000, diluted in blocking buffer). After
blocking, ELISA plates were washed five times with PBST and
50 ll of the standard/sample-detection mixtures was added to the
ELISA plates. Plates were incubated ON at 4°C, while slowly shak-
ing. Absorption at 450 nm was measured after adding 50 ll
substrate solution [100 ll TMB (BD Biosciences OptEIATM)]
followed by stopping buffer (50 ll 1 M H2SO4). The amount of
Ab1–42 was determined with GraphPad Prism 7.0 using a nonlinear
regression model.
Novel object recognition test
Cognitive behavior was assessed by the basic protocol for the NOR
test described by Antunes and Biala (2012). The NOR test is based
on the innate tendency of mice to differentially explore novel
objects over familiar ones. Therefore, mice were placed into the
testing room which is a rectangular, clear open-field area made
from acrylic (40 × 40 × 40 cm). The procedure includes three
phases: habituation, training, and testing. Habituation was
performed in the prior day when the animals were positioned into
the open-field arena without any object to familiarize with the
environment for 5 min. The training phase was performed the day
after the habituation. Mice were placed in the arena facing the
wall opposite to new identical objects which were put at two
opposite positions in the box at the same distance from the nearest
corner. Mice were allowed to freely explore the two objects (A1
and A2) for 5 min and were then returned to their home cage. In
the testing phase, memory was tested either 15 min (STM) or 24 h
(LTM) after the training session. Mice were placed back in the
same box after replacing one of the familiar objects (A1 or A2) by
a novel one (A3 or A4), and the 5-min testing phase was started.
The exploration of the objects was considered as deliberate contact
with their mouth or nose that occurred with each object. The
exploration time for the familiar or the new object during the test
phase was recorded. The percentage preference for the novel
object was calculated using the following formula: % novel object
preference = [novel object exploration time/(novel object explo-
ration time + familiar object exploration time)] × 100%. A value
of 50% reflects no preference for any of the objects, and a value
> 50% indicates preference for the novel object. To exclude the
existence of olfactory clues, all objects were thoroughly cleaned
with 20% ethanol after each trial.
Real-time qPCR
RNA was isolated from choroid plexus and hippocampus using the
Aurum total RNA Mini Kit (Bio-Rad). RNA concentration was
measured using the Nanodrop 1000 (Thermo Scientific), and cDNA
was synthesized by the iScript cDNA Synthesis Kit (Bio-Rad).
qPCR was performed with the Light Cycler 480 system (Roche)
using SensiFast SYBR No-Rox (Bio-Line). Expression levels were
normalized to the expression of the two or three most stable
housekeeping genes, which were determined for each organ and
condition using geNorm (Vandesompele et al, 2002): APP/PS1
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mice choroid plexus: Gapdh and Rpl; hippocampus: b-actin, Hprt,
Rpl. AbO injections in WT or TNFR1/ mice, choroid plexus, and
hippocampus: Gapdh, Hprt, Rpl. The primer sequences of the
forward and reserve primers for the different genes are provided in
Appendix Table S1.
Statistics
Statistics were performed using GraphPad Prism 7.0 (GraphPad Soft-
ware, Inc.). Bars represent mean  SEM. qPCR data were analyzed
with an unpaired t-test unless mentioned differently. Permeability
data and data concerning short-term and LTM data were
compared with one-way ANOVA. Significance levels are indicated
*0.01 ≤ P < 0.05; **0.001 ≤ P < 0.01; ***0.001 ≤ P < 0.0001; and
****P < 0.0001. Exact n- and P-values of the significant results can
be found in Appendix Table S2.
Data availability
The choroid plexus microassay data from this publication have
been deposited to the GEO database (https://www.ncbi.nlm.nih.
gov/geo/) and assigned the identifier GSE110226.
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